Brescia

• The study's aim is to treat adult patients affected by Ph-like ALL, a Philadelphianegative ALL subtype, with a combination of the tyrosine k … Recruiting
  2023-510240-20-00 4 2022-10-05 Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
• A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Ch … Recruiting
  2024-512382-13-00 5 2022-10-04 Migraine (with or without aura)
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia … Recruiting
  2023-510384-36-00 5 2022-09-13 Newly Diagnosed Multiple Myeloma
• An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients wit … Recruiting
  2024-511635-94-00 4 2022-07-11 Relapsed or Refractory Plasmablastic lymphoma
• Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting
  2023-508852-21-00 4 2022-06-10 Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
• Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minima … Recruiting
  2024-515681-14-00 4 2022-05-02 Stage II (pT4)/III colorectal cancer with positive circulating tumor D
• A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer … Recruiting
  2024-512089-32-00 3 2022-03-28 Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
• EORTC 1820-CLTF: Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam th … Recruiting
  2022-502434-10-00 4 2022-02-22 Cutaneous T-cell lymphoma, a category of cancers of lymphocytes (a typ
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim … Recruiting
  2024-510690-16-00 5 2022-01-31 Relapsed/refractory follicular lymphoma
• An Italian multicenter trial with Temozolomide taken daily at low doses continuously in patients with well differentiated neuroendocrine neo … Recruiting
  2024-510898-24-00 4 2022-01-14 Patients with well differentiated neuroendocrine neoplasia (NENs) not
• Treatment with venetoclax consolidated with ibrutinib and rituximab to increase the possibility of minimal residual disease in patient with … Recruiting
  2024-514687-33-00 4 2021-12-21 Previously Untreated Chronic Lymphophatic Leukaemia
• Efficacy and Safety Study of Nipocalimab IV Infusions for Adults With Generalized Myasthenia Gravis Recruiting
  2023-504152-97-00 5 2021-11-26 Generalized Myasthenia Gravis
• Ibrutinib and Obinutuzumab as first-line treatment for patients with Chronic Lymphocytic Leukemia Recruiting
  2024-514824-18-00 4 2021-09-16 chronic lymphocytic leukemia/small lymphocytic lymphoma
• Investigate the efficacy and safety of a bio-marker driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RA … Recruiting
  2024-518534-81-00 4 2021-07-01 metastatic colorectal cancer
• Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting
  2024-512982-15-00 5 2021-06-28 BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
• A study investigating single injection of new botulinum toxin to determine safety and efficacy for treating spasticity in the upper limb Recruiting
  2023-507202-14-00 7 2021-04-29 Upper limb spasticity after stroke or traumatic brain injury
• A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies Recruiting
  2023-504931-42-00 4 2021-04-06 Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters tran
• Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negativ … Recruiting
  2024-515063-66-00 4 2021-03-30 Early stage classical Hodgkin Lymphoma (cHL) without bulky lesions and
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer
• A clinical trial investigating the safety, tolerability, and therapeutic effects of BNT113 in combination with pembrolizumab versus pembroli … Recruiting
  2024-512671-12-00 10 2021-03-05 Unresectable head and neck squamous cell carcinoma, metastatic head an
• “A phase II, single arm study investigating neoadjuvant plus adjuvant treatment with Cemiplimab in surgically resectable, high risk stage II … Recruiting
  2024-515204-39-00 4 2021-02-10 surgically resectable, high risk stage III/IV (M0) Cutaneaous Squamous
• ExclUsive endocRine therapy Or radiation theraPy for women aged ≥70 years with luminal A-like early stage breast cancer (EUROPA): a randomiz … Recruiting
  2023-508094-88-00 5 2021-02-08 breast cancer
• Induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC). PRI … Recruiting
  2024-516798-54-00 4 2021-02-08 HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)
• Randomized phase III trial on NIraparib-Dostarlimab vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peri … Recruiting
  2024-516649-38-00 5 2020-12-01 Recurrent ovarian, fallopian tube or primary peritoneal cancer

Showing 241–264 of 541 trials